“…BACKGROUND: Many people living with HIV have persistent monocyte activation despite viral suppression by antiretroviral therapy (ART), which contributes to non-AIDS complications including neurocognitive and other disorders. Statins have immunomodulatory properties that might be beneficial by reducing monocyte activation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The disease has no existing cure, however, metabolic drugs such as metformin and statins have recently emerged as potential therapeutic candidates. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Additionally, the targeted-group received mineralocorticoid receptor antagonists, statins, angiotensin-converting enzyme inhibitors and/or receptor blockers, and cardiac rehabilitation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A clinical trial, Reduction of Cardiovascular Events with Icosapent Ethyl—Intervention Trial, demonstrated that high-dose EPA (4 g/d icosapent ethyl) reduced composite cardiovascular events in statin-treated high-risk patients. EPA benefits correlated with on-treatment levels, but similar trials using DHA-containing formulations did not show event reduction. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A nomogram was developed as a graphical representation of the model. (3) Results: 14 variables were identified as independent factors contributing to the risk of death for critically ill COVID-19 patients: age (OR 1.08, CI 1.06–1.10), cardiovascular disease (OR 1.64, CI 1.06–2.55), pulmonary disease (OR 1.87, CI 1.16–3.03), baseline Statin treatment (0.54, CI 0.33–0.87), oxygen saturation (unit = 1%, OR 0.94, CI 0.92–0.96), leukocytes (unit 1000/ [Formula: see text] L, OR 1.04, CI 1.01–1.07), lymphocytes (unit 100/ [Formula: see text] L, OR 0.96, CI 0.94–0.99), platelets (unit 100,000/ [Formula: see text] L, OR 0.70, CI 0.62–0.80), procalcitonin (unit ng/mL, OR 1.11, CI 1.05–1.18), kidney failure (OR 1.68, CI 1.05–2.70), congestive heart failure (OR 2.62, CI 1.11–6.21), severe liver failure (OR 4.93, CI 1.94–12.52), and a quick SOFA score of 3 (OR 1.78, CI 1.14–2.78). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…However, the presence of ≥3 risk enhancers reliably identified intermediate‐risk patients that will benefit from statin therapy, and further CAC testing may be considered among those with <3 risk enhancers.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…An independent sample t-test and Chi Square statistic was used to determine statical significance between the two groups. A two-proportion z-test was used to compare visit metrics. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Renin–angiotensin–aldosterone inhibitor, metformin, and statin were prescribed in 89.8%, 66.3%, and 67.1%. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Gender, race, body mass index, presence of co-morbidities such as diabetes and hypertension, and use of steroid, statin, calcium channel blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers were not associated with mortality in the multivariate analysis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Initial treatment, based on European recommendations, included Atorvastatin 20 mg and Ezetimibe 10 mg and led to a decrease in LDL-C by 46% for 5 months; however, the patient developed severe statin intolerance. Atorvastatin was replaced with Rosuvastatin 10 mg, but the symptoms persisted. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Atorvastatin, a potent statin, possesses pleiotropic effects including immunomodulatory, lipid-lowering, and anti-inflammatory. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Possible supplementary therapy for this condition is hydroxychloroquine. Statins, rituximab, and novel anticoagulant medicines are all potential future treatments for non-pregnant individuals with antiphospholipid syndrome. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The aim of the present study was to assess the potential benefit of statins as an adjuvant to chemotherapy. We show that simvastatin synergizes with conventional chemotherapy drugs in terms of cell viability, tumor growth, and dissemination and represents valuable alternative adjuvant therapy that needs further investigation in clinical trials. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The measured surface dose differences between linear accelerators are not statically significant (P>0.989). Similarly, the surface dose difference between SSD and SAD setup was also analysed and had no statistical significance (P>0.849). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Notably, pleiotropic drugs, like statins, liraglutide and metformin, affect miR-34a expression. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In addition, inhibition of cholesterol synthesis with statin resulted in a phenotype similar to that of methionine removal and a decrease in stem cell markers and snoRNA ACA43. …”
Enlace del recurso
Enlace del recurso

“…After adjustment for vascular risk factors and statin pre-treatment, the effect sizes remained essentially unchanged. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: This was a cross-sectional study in 395 non-diabetic individuals (209 CKD and 186 non-diabetic and non-CKD) without statin therapy. Vascular ultrasound examination assessing 10 territories was combined with advanced lipoprotein testing performed by nuclear magnetic resonance spectroscopy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The association was maintained after further adjustment for comorbidities, statin treatment and markers of malnutrition. While in females this association was linear, in males it showed a U-shaped curve. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Molecular and immunohistochemical expression of both LTA4H and FXR1 did not statically correlate with mitotic count or Ki-67 index. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso